Search Results - "Zvezdana Hlebanja"

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial by Skof, Erik, Rebersek, Martina, Hlebanja, Zvezdana, Ocvirk, Janja

“…Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC). There…”
Get full text

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience by Ocvirk, Janja, Moltara, Maja Ebert, Mesti, Tanja, Boc, Marko, Rebersek, Martina, Volk, Neva, Benedik, Jernej, Hlebanja, Zvezdana

“…Metastatic colorectal cancer (mCRC) is mainly a disease of elderly, however, geriatric population is underrepresented in clinical trials. Patient registries…”
Get full text

Recommendations from the Institute of Oncology Ljubljana for the treatment of patients with gastric cancer by Erik Brecelj, Vesna Zadnik, Neva Volk, Mateja Krajc, Ana Blatnik, Ksenija Strojnik, Nina Boc, Marianna Yasmin Hunt, Gorana Gašljević, Jera Jeruc, Srdjan Novaković, Marko Boc, Franc Anderluh, Martina Reberšek, Borut Štabuc, Irena Oblak, Janja Ocvirk, Ana Jeromen Peressutti, Zvezdana Hlebanja, Tanja Mesti, Marija Ignjatović, Nežka Hribernik, Ibrahim Edhemović, Gašper Pilko, Rok Petrič, Ajra Šečerov Ermenc, Nada Rotovnik Kozjek, Vaneja Velenik, Sonja Kramer, Maja Ebert Moltara, Jernej Benedik

Get full text

Recommendations for the diagnosis and treatment of patients with colorectal cancer by Erik Brecelj, Vaneja Velenik, Martina Reberšek, Nina Boc, Irena Oblak, Vesna Zadnik, Mateja Krajc, Snježana Frković Grazio, Gorana Gašljević, Srdjan Novaković, Maja Ebert Moltara, Franci Anderluh, Ajra Šečerov Ermenc, Ibrahim Edhemović, Gašper Pilko, Rok Petrič, Blaž Trotovšek, Nada Rotovnik Kozjek, Tamara Joksimović, Andreja C. Škufca Smrdel, Peter Popovič, Marianna Yasmin Hunt, Sonja Kramer, Janja Ocvirk, Ana Jeromen Peressutti, Mirko Omejc, Stojan Potrč, Bojan Krebs, Borut Štabuc, Aleš Tomažič, Maja Mušič, Neva Volk, Marko Boc, Zvezdana Hlebanja, Tanja Mesti, Marija Ignjatović, Ana Blatnik, Nežka Hribernik, Jernej Benedik

Get full text

KRAS, NRAS and BRAF mutational status and first line treatment patterns in Slovenian population with metastatic colorectal carcinoma: Five year results by Mesti, Tanja, Boc, Marko, Rebersek, Martina, Hlebanja, Zvezdana, Volk, Neva, Ocvirk, Janja

“…Abstract only e15546 Background: A phase IV non-interventional study was performed from 2013 till 2018 including 650 patients with primary aim to assess KRAS,…”
Get full text

Continous treatment with bevacizumab in patients with metastatic colorectal cancer by Ocvirk, Janja, Rebersek, Martina, Boc, Marko, Volk, Neva, Benedik, Jernej, Hlebanja, Zvezdana

“…Abstract only…”
Get full text

Bevacizumab-Containing Chemotherapy in Elderly Patients with Metastatic Colorectal Cancer by Jernej, Benedik, Marko, Boc, Zvezdana, Hlebanja, Neva, Volk, Martina, Rebersek, Janja, Ocvirk, Tanja, Mesti

Get full text

Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer by Ocvirk, Janja, Reberšek, Martina, Skof, Erik, Hlebanja, Zvezdana, Boc, Marko

“…The aim of this study was to compare the efficacy and safety of the epirubicin, cisplatin, and continuous infusion of 5-fluorouracil (ECF) regimen with that of…”
Get full text

PD-0015 Influence of BRAF V600E and Different Kras Mutations on Outcome of Metastatic Colorectal Cancer Patients Treated with First- Line Therapy by Rebersek, Martina, Boc, Marko, Hlebanja, Zvezdana, Volk, Neva, Benedik, Jernej, Ebert, Maja, Mesti, Tanja, Ocvirk, Janja

Get full text

Capecitabine plus Irinotecan as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial by Skof, Erik, Rebersek, Martina, Hlebanja, Zvezdana, Ocvirk, Janja

“…Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC). There…”
Get full text

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial by Hlebanja, Zvezdana, Skof, Erik, Rebersek, Martina, Ocvirk, Janja

“…Background Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer…”
Get full text

Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis by Rebersek, Martina, Boc, Marko, Cerkovnik, Petra, Benedik, Jernej, Hlebanja, Zvezdana, Volk, Neva, Novakovic, Srdjan, Ocvirk, Janja

“…KRAS mutation status in codons 12 and 13 is recognized as a predictive factor for resistance to anti-EGFR monoclonal antibodies. Despite having a wild type…”
Get full text

Bolnica s primarno razsejanim karcinomom danke z zasevki v jetrih by Marko Boc, Martina Reberšek, Zvezdana Hlebanja, Nina Boc, Janja Ocvirk

“…Rak debelega črevesa in danke (RDČD) je najpogostejši rak v Sloveniji. Po podatkih Registra raka Slovenije za leto 2008 je v Sloveniji zbolelo 1.450 ljudi(1)…”
Get full text

Spontaneous regression of hepatocellular carcinoma by Markovic, S, Ferlan-Marolt, V, Hlebanja, Z

“…Spontaneous regression of a histologically proven hepatocellular carcinoma was observed in a 62-yr-old male Slovenian patient with HBsAg-positive liver…”
Get more information

Smernice za zdravljenje bolnikov z rakom požiralnika in ezofagogastričnega stika (EGS) by Franc Anderluh, Jasna But-Hadžić, Anton Crnjac, Goran Gačevski, Zvezdana Hlebanja, Irena Oblak, Janja Ocvirk, Martina Reberšek, Mihael Sok, Matevž Srpčič, Ajra Šečerov Ermenc, Borut Štabuc, Vaneja Velenik, Neva Volk

“…Rak požiralnika je razmeroma redek tumor z veliko umrljivostjo. Pogosteje zbolijo moški v 6. ali 7. desetletju življenja. V zadnjih letih v zahodnem svetu…”
Get full text

Dopolnjena priporočila za sistemsko zdravljenje bolnikov z napredovalim karcinomom želodca, 2010 by Martina Reberšek, Janja Ocvirk, Zvezdana Hlebanja, Jernej Benedik, Neva Volk

“…Ni abstrakta…”
Get full text

Dopolnjena priporočila za sistemsko zdravljenje bolnikov z napredovalim rakom debelega črevesa in danke - 2009 by Martina Reberšek, Janja Ocvirk, Zvezdana Hlebanja, Jernej Benedik, Neva Volk

“…Metastatski rak debelega črevesa in danke je večinoma še vedno neozdravljiva bolezen, vendar sta se prognoza in preživetje teh bolnikov v zadnjih 6 letih močno…”
Get full text